tirzepatide rhabdomyolysis Should be discontinued if a patient develops rhabdomyolysis? An Incidental Finding of a

A medication that may be included for the personalized plan based on the patients needs

ASEAN, Association of Southeast Asian Nations

However, stacking these treatments without medical guidance can increase risks of gastrointestinal side effects, blood sugar fluctuations, and unexpected drug-supplement interactions

As of June 2025, the FDA removed both semaglutide and tirzepatide from its drug shortage list, a move that limits when and how pharmacies can legally compound these medications

The clinical expert stated that expected use of semaglutide tablets is aligned with the indication and that semaglutide tablets would be used as an add-on treatment in patients with T2DM when metformin is no longer effective as monotherapy (second-line treatment), as a first-line treatment when metformin is not tolerated, and as a third-line treatment on occasion

Besides, GLP-1 and GLP-1RAs can interact with other signaling pathways [15]